Education
About Us
Working with TipRanks
Follow Us
Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
Total Valuation
Scinai Immunotherapeutics has a market cap or net worth of $963.88K. The enterprise value is $8.60M.
Market Cap$963.88K
Enterprise Value$8.60M
Share Statistics
Scinai Immunotherapeutics has 3,187,679 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,187,679
Owned by Insiders7.40%
Owned by Institutions<0.01%
Financial Efficiency
Scinai Immunotherapeutics’s return on equity (ROE) is 0.48 and return on invested capital (ROIC) is -71.59%.
Return on Equity (ROE)0.48
Return on Assets (ROA)0.36
Return on Invested Capital (ROIC)-71.59%
Return on Capital Employed (ROCE)-0.74
Revenue Per Employee21.23K
Profits Per Employee154.71K
Employee Count31
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Scinai Immunotherapeutics is 0.2. Scinai Immunotherapeutics’s PEG ratio is -0.00415.
PE Ratio0.2
PS Ratio4.11
PB Ratio0.27
Price to Fair Value0.27
Price to FCF-0.43
Price to Operating Cash Flow-0.29
PEG Ratio-0.00415
Income Statement
In the last 12 months, Scinai Immunotherapeutics had revenue of 658.00K and earned 4.80M in profits. Earnings per share was 6.00.
Revenue658.00K
Gross Profit-580.00K
Operating Income-8.64M
Pretax Income4.80M
Net Income4.80M
EBITDA-6.99M
Earnings Per Share (EPS)6.00
Cash Flow
In the last 12 months, operating cash flow was -5.69M and capital expenditures -16.00K, giving a free cash flow of -5.71M billion.
Operating Cash Flow-5.69M
Free Cash Flow-5.71M
Free Cash Flow per Share-1.79
Dividends & Yields
Scinai Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.15
52-Week Price Change-64.91%
50-Day Moving Average1.38
200-Day Moving Average2.26
Relative Strength Index (RSI)32.32
Average Volume (3m)101.31K
Important Dates
Scinai Immunotherapeutics upcoming earnings date is Nov 26, 2025, TBA (Confirmed).
Last Earnings DateAug 21, 2025
Next Earnings DateNov 26, 2025
Ex-Dividend Date―
Financial Position
Scinai Immunotherapeutics as a current ratio of 1.32, with Debt / Equity ratio of 29.98%
Current Ratio1.32
Quick Ratio1.32
Debt to Market Cap0.10
Net Debt to EBITDA0.02
Interest Coverage Ratio-6.00
Taxes
In the past 12 months, Scinai Immunotherapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Scinai Immunotherapeutics EV to EBITDA ratio is 0.36, with an EV/FCF ratio of -0.44.
EV to Sales4.29
EV to EBITDA0.36
EV to Free Cash Flow-0.44
EV to Operating Cash Flow-0.45
Balance Sheet
Scinai Immunotherapeutics has $989.00K in cash and marketable securities with $2.36M in debt, giving a net cash position of -$1.37M billion.
Cash & Marketable Securities$989.00K
Total Debt$2.36M
Net Cash-$1.37M
Net Cash Per Share-$0.43
Tangible Book Value Per Share$12.37
Margins
Gross margin is -146.99%, with operating margin of -1312.77%, and net profit margin of 728.88%.
Gross Margin-146.99%
Operating Margin-1312.77%
Pretax Margin728.88%
Net Profit Margin728.88%
EBITDA Margin1195.59%
EBIT Margin-1312.77%
Analyst Forecast
The average price target for Scinai Immunotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast306.41%
EPS Growth Forecast―